08:00 , Dec 22, 2008 |  BC Week In Review  |  Clinical News

Alitretinoin: Phase III started

Basilea began the double-blind, U.S. Phase III HANDEL trial to compare oral alitretinoin vs. placebo for up to 24 weeks in 600 patients who do not respond to topical steroids. The company markets alitretinoin as...
08:00 , Feb 9, 1998 |  BC Week In Review  |  Company News

INSERM other research news

French researchers published in Science the loss of dopamine function in mice mutated to lack various retinoid receptors in the brain. The knockout mice showed statistically significant reductions in standard movement tests of dopamine-mediated motor...